TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

In the expanding precision oncology market, Tempus AI (TEM) and Illumina (ILMN) present contrasting investment profiles; TEM projects substantial 82% 2025 sales growth and positive adjusted EBITDA, driven by diagnostic innovation and partnerships, while ILMN, despite recent stock underperformance, demonstrates operational efficiency, improved margins, and expanded oncology solutions, positioning it as the more attractively valued option with strong projected 2025 EPS of $4.45-$4.55.

Analysis

The precision oncology sector presents a distinct divergence between Tempus AI (TEM) and Illumina (ILMN), representing a classic growth versus value scenario. Tempus AI is on a high-growth trajectory, evidenced by a 61.2% stock surge over the past year and an upgraded 2025 revenue forecast of approximately $1.26 billion, implying nearly 82% annual growth. This is supported by tangible operational improvements, including a 1649 bps expansion in adjusted gross margin and a narrowing adjusted EBITDA loss to negative $5.6 million in the second quarter, with a projection for positive adjusted EBITDA in 2025. This momentum is fueled by strategic partnerships with firms like AstraZeneca and product innovations such as the xM liquid biopsy. Conversely, Illumina has seen its stock decline 25.2% and projects a slight revenue decrease of 0.5-2.5% for 2025. However, the company demonstrates significant operational strength, improving its non-GAAP operating margin by 160 basis points year-over-year to 23.8% and raising its 2025 non-GAAP EPS guidance to a range of $4.45-$4.55. ILMN's strategy hinges on strengthening its market-leading position with its TruSight Oncology 500 assay and expanding its IVD portfolio. This operational efficiency and profitability come at a more attractive valuation, with a forward price-to-sales ratio of 3.34, below its one-year median, compared to TEM's premium multiple of 9.36.

Key Decisions for Investors

• Growth-oriented investors should evaluate Tempus AI for its aggressive top-line expansion, projected at 82% for 2025, and its clear path to positive adjusted EBITDA, while acknowledging the premium valuation reflected in its 9.36 forward price-to-sales ratio.
• Value-focused investors may find Illumina compelling due to its demonstrated operational leverage, with non-GAAP operating margins expanding to 23.8% and a raised 2025 EPS forecast, which is available at a more attractive valuation if its modest revenue decline can be stabilized.
• Given the stark performance and valuation divergence, investors should monitor key catalysts, namely Tempus AI's execution on achieving its positive EBITDA target and Illumina's ability to translate product advancements like the TSO 500 upgrade into a revenue inflection.